Novel anti-cd47 antibodies and uses thereof
By designing CD47 antibodies with specific sequences, the problem of blood toxicity caused by existing antibodies has been solved, achieving effective cancer treatment while reducing adverse reactions to the blood system.
CN122396701APending Publication Date: 2026-07-14I MAB BIOPHARMA (HANGZHOU) CO LTD
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- I MAB BIOPHARMA (HANGZHOU) CO LTD
- Filing Date
- 2024-12-06
- Publication Date
- 2026-07-14
Smart Images
Figure FT_1 
Figure FT_2 
Figure FT_3
Abstract
Provided herein are anti-CD47 antibodies and immunologically active fragments thereof that have prolonged anti-tumor effects and cause low or no depletion of red blood cells or platelets and coagulopathy. Also provided are pharmaceutical compositions containing such antibodies or antibody fragments, as well as methods of treatment using such antibodies, for example, as a single agent or in combination with one or more other therapeutic agents.
Need to check novelty before this filing date? Find Prior Art